-
Plos Med: Breast cancer patients are at higher risk of anxiety and depression!
Time of Update: 2021-03-19
Recently, a study published in the journal Plos Med showed that compared with women without cancer, breast cancer survivors have a higher risk of anxiety, depression, sleep, sexual dysfunction, fatigue, and pain.
-
Eur Radiol: The influence of CT slice thickness in radiomics model in predicting survival rate of non-small cell lung cancer
Time of Update: 2021-03-19
Table 2 In the validation set, three radioomics models with different layer thicknesses are used to predict the performance of DFS.
CT layer thickness has no significant impact on the performance of the radiomic model for predicting DFS in patients with non-small cell lung cancer.
-
Br J Cancer: HPV-positive oropharyngeal squamous cell carcinoma changes to the gut microbiome after radiotherapy and chemotherapy
Time of Update: 2021-03-19
In this study, the researchers analyzed the oral and intestinal microbiome in the cohort of HPV+OPSCC patients and evaluated the impact of radiotherapy and chemotherapy (CRT).
-
Eur Radiol: Patients with soft tissue sarcoma should be alert to the presence of chest metastases!
Time of Update: 2021-03-19
Soft tissue sarcoma (Soft tissue sarcoms, STS) is the origin of malignant lesions fingers leaves, there are a variety of histological subtypes, currently classified according to World Health Organization classification of tumors of bone and soft tissue 2020.
-
Ilixadencel treatment of kidney cancer, the patient's survival period can be significantly prolonged
Time of Update: 2021-03-19
Biopharmaceutical company Immunicum today announced that in the updated data of the phase II MERECA randomized trial, ilixadencel combined with sunitinib has achieved positive results in the first-line treatment of patients with metastatic renal cell carcinoma (mRCC).
-
China NMPA accepts application for clinical trial of PD-1/TGF-β bifunctional fusion protein
Time of Update: 2021-03-19
(Junshi Biosciences) announced that its clinical trial application PD-1 / TGF-β bifunctional fusion protein injection JS201 (JS201) has been China's State Drug Administration accepted Bureau (NMPA).
Its anti-PCSK9 monoclonal antibody is the first clinical trial approved by NMPA in China.
-
J Immunother Cancer: Nanoencapsulated rituximab mediates excellent cellular immunity against metastatic B-cell lymphoma in a humanized mouse model with complement activity
Time of Update: 2021-03-19
NSG- Hc1 mice can be used as a viable model, which can be used to study the use of cancer-targeted anti-tumor therapies, and to understand the induction mechanism of anti-tumor cell immune responses.
-
Eur Radiol: Feasibility study of MRI-guided breast biopsy based on diffusion-weighted imaging
Time of Update: 2021-03-19
We identified 64 of 87 operations that can detect lesions in DWI; added DWI sequences to the standard protocol to locate lesions and biopsy devices, and evaluate the correct location of site markers.
-
Bleeding gums is not a small problem!
Time of Update: 2021-03-19
However, when the liver is affected by diseases such as hepatitis, cirrhosis or cancer, its function will be reduced, and the bacteria can survive longer, so it may cause more damage.
Secondly, reactive oxygen metabolites may be the physiopathological link between periodontitis and liver cancer.
-
Eur Radiol: How to evaluate the efficacy of sorafenib for advanced liver cancer?
Time of Update: 2021-03-19
An independent predictor of progressive survival (PFS), and verified that LS can predict the occurrence of significant liver injury (grade ≥3) after sorafenib administration, providing a new reference for the clinical development of personalized treatment plans for patients with advanced HCC in accordance with.
-
J Clin Oncol: Phase 3 trial results of Andecaliximab combined with mFOLFOX6 as a first-line therapy for advanced gastric/gastroesophageal junction adenocarcinoma
Time of Update: 2021-03-19
This study is a randomized, double-blind, placebo (PBO)-controlled multicenter Phase III study, which aims to evaluate mFOLFOX6 with or without ADX in the treatment of untreated human epidermal growth factor receptor 2 negative gastric cancer or GEJ glands Efficacy and safety of cancer.
-
Nat Med: Research on the treatment resistance of metastatic castration-resistant prostate cancer
Time of Update: 2021-03-19
The current treatment strategy for metastatic castration-resistant prostate cancer (mCRPC) is the second-generation androgen-targeted therapy, including enzalutamide and abiraterone.
The current treatment strategy for metastatic castration-resistant prostate cancer (mCRPC) is the second-generation androgen-targeted therapy, including enzalutamide and abiraterone.
-
Eur Radiol: What are the main points of MRI diagnosis for hepatocellular carcinoma of less than 1cm?
Time of Update: 2021-03-19
Recently, a study published in the journal European Radiology determined the best non-invasive diagnostic criteria for subcentimeter HCC by using gadoxetate disodium-enhanced MRI, and evaluated its effects on untreated patients at risk of HCC and eligible for radical treatment.
-
AstraZeneca withdraws Imfinzi's advanced bladder cancer indication in the U.S.
Time of Update: 2021-03-19
For patients with tumor cells and/or tumor infiltrating immune cells with high expression (≥25%) PD-L1, compared with standard treatment, Imfinzi monotherapy did not achieve the primary endpoint of improving overall survival (OS).
-
Lancet Oncol: Fudan Zhongshan Hospital confirmed the value of secondary surgery for recurrent ovarian cancer!
Time of Update: 2021-03-19
Corresponding to the German phase III DESKTOP study, the SOC-1 study once again confirmed that the second cytoreductive surgery can bring progression-free survival (PFS) benefits for patients with platinum-sensitive recurrent ovarian cancer.
-
Merck autonomously withdraws Keytruda in the U.S. for indications for metastatic small cell lung cancer
Time of Update: 2021-03-19
On March 1, Merck announced the voluntary withdrawal of Keytruda (pembrolizumab) in the United States for the treatment of patients with metastatic small cell lung cancer (SCLC) who have undergone platinum-based chemotherapy and at least one other treatment regimen or after the disease has progressed.
-
Nat Commun: CD318, TSPAN8 and CD66c are candidate targets for CAR-T cell therapy for pancreatic cancer
Time of Update: 2021-03-19
Among the CAR-T cells specific for CD66c, CD318, and TSPAN8, CD318 has shown the efficacy of stabilizing the disease to completely eradicating tumors, followed by TSPAN8, which is the most promising potential based on functionality and predicted safety Candidate targets.
1038/s41467-021-21774-4">Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma .
-
Nat Med: Patients with multiple myeloma may cause BCMA homozygous deletion after BCMA-targeted CAR-T treatment
Time of Update: 2021-03-19
1038/s41591-021-01245-5">Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma .
1038/s41591-021-01245-5">Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma Leave a message here
-
Why does Junshi PD-1 cooperate with AstraZeneca?
Time of Update: 2021-03-19
According to the press release, Junshi Biologics has the exclusive right to promote all the approved indications (melanoma and nasopharyngeal carcinoma) of teriprizumab in non-core markets in China, as well as urinary system tumors (urinary tract tumors) that will be approved for marketing in the future.
-
The second domestic third-generation EGFR-TKI was approved for listing
Time of Update: 2021-03-19
At the same time, the drug is targeted at EGFR exon 19 deletion or extracellular The Phase III clinical trial for the treatment (first-line treatment) of adult patients with locally advanced or metastatic non-small cell lung cancer with a substitution mutation of Exon 21 (L858R) was launched in June 2019, and it is expected to submit a marketing application in 2022.
